(Note: GRAIL, Inc., withdrew its IPO plans on Aug. 23, 2021, following completion of its acquisition on Aug. 18, 2021, by Illumina. The U.S. Federal Trade Commission is challenging the acquisition and the matter is set to go to trial today – Aug. 24, 2021, at the FTC. This case marks the first “vertical” trial in years, Reuters reported. The European Union is also critical of Illumina for completing the deal without regulatory approval. The EU began an investigation in June of the pending merger. GRAIL had filed to go public in September 2020. In 2015, GRAIL was formed within Illumina. In 2016, GRAIL received investments from third parties and began operating as a stand-alone company, the prospectus says.)

We are a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection.

Our multi-cancer early detection blood test, Galleri, is designed as a screening test for asymptomatic individuals over 50 years of age. We plan to commercially launch Galleri in 2021 as a laboratory developed test. In a clinical study, an earlier version of Galleri identified over 50 types of cancers, over 45 of which lack recommended screenings. (These cancers include cancer of the bladder, the anorectal area, the esophagus, the pancreas , the liver, the ovary and the uterus, as well as melanoma.) Data showed that when our test detected a cancer, it was also able to localize the cancer signal with high accuracy.